Resources for Collectors

This page includes resources and information for the blood community regarding CCP. AABB will be regularly updating this page with content. If you have resources you wish to share or see please contact AABB.

Collection of CCP can be implemented immediately by AABB-accredited blood collectors. Collection, labeling and distribution of CCP should follow the recommendations in FDA’s February 2021 Guidance document. CCP is not an FDA-approved blood product and must be collected, tested, labeled and distributed under an FDA-approved IND or under FDA’s emergency use authorization for unlicensed CCP which must be tested and labeled at high-titer CCP for treatment of hospitalized COVID-19 patients as described in the current FDA guidance:

Investigational COVID-19 Convalescent Plasma; Guidance for Industry (Updated February 2021)

AABB has posted a toolkit for CCP under the EUA to assist with the recently updated Guidance and Feb 23, 2021 EUA

AABB COVID-19 Convalescent Plasma Town Hall On-Demand eCast Series

(complimentary to AABB members through the support of Cerus Corporation)


This on-demand eCast series discusses the vein-to-vein considerations of collection and administration of COVID-19 convalescent plasma (CCP). It is presented in two segments: Donor Recruitment Considerations and Hospital Considerations.

Learn More